Search Results - "Miller, TP"

A Clinical Analysis of Two Indolent Lymphoma Entities: Mantle Cell Lymphoma and Marginal Zone Lymphoma (Including the Mucosa-Associated Lymphoid Tissue and Monocytoid B-Cell Subcategories): A Southwest Oncology Group Study by Fisher, Richard I., Dahlberg, Steve, Nathwani, Bharat N., Banks, Peter M., Miller, Thomas P., Grogan, Thomas M.

“…The objectives of this study were (1) to determine the clinical presentation and natural history associated with two newly recognized pathologic entities…”
Get full text

New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma by FISHER, Richard I, LEBLANC, Michael, PRESS, Oliver W, MALONEY, David G, UNGER, Joseph M, MILLER, Thomas P

“…The natural history of follicular lymphoma is believed not to have changed over the last 30 years. Median survivals have ranged from 7 to 10 years, and the…”
Get full text

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells by Dave, Sandeep S, Wright, George, Tan, Bruce, Rosenwald, Andreas, Gascoyne, Randy D, Chan, Wing C, Fisher, Richard I, Braziel, Rita M, Rimsza, Lisa M, Grogan, Thomas M, Miller, Thomas P, LeBlanc, Michael, Greiner, Timothy C, Weisenburger, Dennis D, Lynch, James C, Vose, Julie, Armitage, James O, Smeland, Erlend B, Kvaloy, Stein, Holte, Harald, Delabie, Jan, Connors, Joseph M, Lansdorp, Peter M, Ouyang, Qin, Lister, T. Andrew, Davies, Andrew J, Norton, Andrew J, Muller-Hermelink, H. Konrad, Ott, German, Campo, Elias, Montserrat, Emilio, Wilson, Wyndham H, Jaffe, Elaine S, Simon, Richard, Yang, Liming, Powell, John, Zhao, Hong, Goldschmidt, Neta, Chiorazzi, Michael, Staudt, Louis M

“…Patients with follicular lymphoma may survive for periods ranging from less than a year to several decades. In this study, DNA-microarray analysis of gene…”
Get full text

Utility of Fine-Needle Aspiration As a Diagnostic Technique in Lymphoma by HEHN, Sean T, GROGAN, Thomas M, MILLER, Thomas P

“…To evaluate, from a clinician's perspective, the sensitivity and specificity of fine-needle aspiration (FNA) as a technique for the diagnosis of lymphoma…”
Get full text

Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial by Miller, TP, Grogan, TM, Dahlberg, S, Spier, CM, Braziel, RM, Banks, PM, Foucar, K, Kjeldsberg, CR, Levy, N, Nathwani, BN

“…The growth fraction of tumors from patients with non-Hodgkin's lymphomas (NHL) has been shown to correlate with survival in retrospective studies. The growth…”
Get full text

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma by Rosenwald, Andreas, Wright, George, Wiestner, Adrian, Chan, Wing C, Connors, Joseph M, Campo, Elias, Gascoyne, Randy D, Grogan, Thomas M, Muller-Hermelink, H.Konrad, Smeland, Erlend B, Chiorazzi, Michael, Giltnane, Jena M, Hurt, Elaine M, Zhao, Hong, Averett, Lauren, Henrickson, Sarah, Yang, Liming, Powell, John, Wilson, Wyndham H, Jaffe, Elaine S, Simon, Richard, Klausner, Richard D, Montserrat, Emilio, Bosch, Francesc, Greiner, Timothy C, Weisenburger, Dennis D, Sanger, Warren G, Dave, Bhavana J, Lynch, James C, Vose, Julie, Armitage, James O, Fisher, Richard I, Miller, Thomas P, LeBlanc, Michael, Ott, German, Kvaloy, Stein, Holte, Harald, Delabie, Jan, Staudt, Louis M

“…We used gene expression profiling to establish a molecular diagnosis of mantle cell lymphoma (MCL), to elucidate its pathogenesis, and to predict the length of…”
Get full text

Prognostic significance of the Ki-67 : associated proliferative antigen in aggressive non-Hodgkin's lymphomas : a prospective Southwest oncology group trial by MILLER, T. P, GROGAN, T. M, SCHNITZER, B, TUBBS, R. R, GAYNOR, E. R, FISHER, R. I, DAHLBERG, S, SPIER, C. M, BRAZIEL, R. M, BANKS, P. M, FOUCAR, K, KJELDSBERG, C. R, LEVY, N, NATHWANI, B. N

“…The growth fraction of tumors from patients with non-Hodgkin's lymphomas (NHL) has been shown to correlate with survival in retrospective studies. The growth…”
Get full text

Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition : Therapeutic implications by FERNANDEZ, Yolanda, VERHAEGEN, Monique, MILLER, Thomas P, RUSH, Jenny L, STEINER, Philipp, OPIPARI, Anthony W, LOWE, Scott W, SOENGAS, Maria S

“…Melanoma is the most aggressive form of skin cancer and advanced stages are invariably resistant to conventional therapeutic agents. Using bortezomib as a…”
Get full text

The limits of limited stage lymphoma by Miller, Thomas P

Get full text

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project by Rimsza, Lisa M., Roberts, Robin A., Miller, Thomas P., Unger, Joseph M., LeBlanc, Michael, Braziel, Rita M., Weisenberger, Dennis D., Chan, Wing C., Muller-Hermelink, H. Konrad, Jaffe, Elaine S., Gascoyne, Randy D., Campo, Elias, Fuchs, Deborah A., Spier, Catherine M., Fisher, Richard I., Delabie, Jan, Rosenwald, Andreas, Staudt, Louis M., Grogan, Thomas M.

“…The Leukemia and Lymphoma Molecular Profiling Project recently published results from DNA microarray analyses of 240 diffuse large B-cell lymphomas (DLBCLs)…”
Get full text

Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma by Miller, Thomas P, Dahlberg, Steve, Cassady, J. Robert, Adelstein, David J, Spier, Catherine M, Grogan, Thomas M, LeBlanc, Michael, Carlin, Susan, Chase, Ellen, Fisher, Richard I

“…Patients with intermediate- or high-grade non-Hodgkin's lymphoma can be cured with doxorubicin-containing combination chemotherapy. 1 The cure rate varies…”
Get full text

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma by CZUCZMAN, Myron S, THALL, Aron, SWEETENHAM, John, ALKUZWENY, Baha, FINUCANE, Deborah M, LEIGH, Bryan R, WITZIG, Thomas E, VASE, Julie M, YOUNES, Anas, EMMANOUILIDES, Christos, MILLER, Thomas P, MOORE, Joseph O, LEONARD, John P, GORDON, Leo I

“…This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with…”
Get full text

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 by Press, Oliver W., Unger, Joseph M., Braziel, Rita M., Maloney, David G., Miller, Thomas P., LeBlanc, Michael, Gaynor, Ellen R., Rivkin, Saul E., Fisher, Richard I.

“…Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG) conducted a phase 2 trial…”
Get full text

Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures by Mahadevan, Daruka, Spier, Catherine, Della Croce, Kimiko, Miller, Susan, George, Benjamin, Riley, Chris, Warner, Stephen, Grogan, Thomas M, Miller, Thomas P

“…To glean biological differences and similarities of peripheral T-cell lymphoma–not otherwise specified [PTCL-NOS] to diffuse large B-cell lymphoma (DLBCL), a…”
Get full text

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions by Rimsza, Lisa M., Roberts, Robin A., Campo, Elias, Grogan, Thomas M., Bea, Silvia, Salaverria, Itziar, Zettl, Andreas, Rosenwald, Andreas, Ott, German, Muller-Hermelink, H. Konrad, Delabie, Jan, Fisher, Richard I., Unger, Joseph M., LeBlanc, Michael, Staudt, Louis M., Jaffe, Elaine S., Gascoyne, Randy D., Chan, Wing C., Weisenburger, Dennis D., Greiner, Timothy, Braziel, Rita M., Miller, Thomas P.

“…Decreased major histocompatibility class II (MHCII) expression is associated with poor survival in diffuse large B-cell lymphoma (DLBCL). Immune-privileged…”
Get full text

Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death by Fernández, Yolanda, Miller, Thomas P, Denoyelle, Christophe, Esteban, Jose A, Tang, Wen-Hua, Bengston, Audrey L, Soengas, María S

“…The proteasome inhibitor bortezomib is emerging as a potent anti-cancer agent. Still, recent clinical trials have revealed a significant secondary toxicity of…”
Get full text

Independent Prognostic Significance of a Nuclear Proliferation Antigen in Diffuse Large Cell Lymphomas as Determined by the Monoclonal Antibody Ki-67 by Grogan, Thomas M., Lippman, Scott M., Spier, Catherine M., Slymen, Donald J., Rybski, James A., Rangel, Catherine S., Richter, Lynne C., Miller, Thomas P.

“…To assess the prognostic significance of the growth fraction in diffuse large cell lymphoma (DLCL), we studied 105 DLCL patients with the monoclonal antibody…”
Get full text

Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas by de Vos, Sven, Hofmann, Wolf-Karsten, Grogan, Thomas M, Krug, Utz, Schrage, Mathew, Miller, Thomas P, Braun, Jonathan G, Wachsman, William, Koeffler, H Phillip, Said, Jonathan W

“…Follicular lymphoma (FL) is characterized by a continuous rate of relapse and transformation to a high-grade lymphoma, usually diffuse large B-cell lymphoma…”
Get full text

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease by PRESS, Oliver W, LEBLANC, Michael, LICHTER, Allen S, GROGAN, Thomas M, UNGER, Joseph M, WASSERMAN, Todd H, GAYNOR, Ellen R, PETERSON, Bruce A, MILLER, Thomas P, FISHER, Richard I

“…The management of early-stage Hodgkin's disease in the United States is controversial. To evaluate whether staging laparotomy could be safely avoided in…”
Get full text

REM Sleep Behavior Disorder: Potential Relationship to Post-traumatic Stress Disorder by Husain, Aatif M, Miller, Patricia P, Carwile, Sandra T

“…SUMMARYRapid eye movement sleep behavior disorder (RBD) is aparasomnia in which there is enactment, often violent, of dream mentation.Although this syndrome is…”
Get full text